Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
WESTON, Fla., Oct. 24, 2018 /PRNewswire/ -- Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today publication of preclinical data evaluating 2HPβCD in experimental models of Alport Syndrome and FSGS. Data were published in Kidney International.1
Key findings from the experimental Alport Syndrome model (Col4a3 knockout mice) include:
Key findings from the experimental FSGS mouse model (Adriamycin-induced nephropathy) include:
The authors reported that these data are supportive of that from their previous studies in an experimental model of diabetic kidney disease and a newly established FSGS model (NFAT mouse model), both of which demonstrated a preventive effect of 2HPβCD in progression of kidney disease.
"We are pleased to see the preclinical data published in the prestigious Kidney International journal," stated Stephen C. Glover, Variant's Co-founder, CEO and Chairman. "The strength of these data helped support progressing directly into phase 2a clinical trials in adult patients with FSGS, which will significantly shorten our development time. We look forward to advancing our goal to provide a meaningful treatment for FSGS, AS, and other forms of kidney disease."
Variant Pharmaceuticals, a clinical stage orphan drug company focusing on restoring health and transforming the lives of patients with rare diseases through innovation, was established in 2014, with the mission to become a leading orphan drug company. Our evolving product pipeline is targeted to the $100+ billion orphan drug market. Our lead candidate is 2-hydroxypropyl-β-cyclodextrin (2HPβCD) for chronic treatment of two orphan indications, Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS), progressive forms of kidney disease with an addressable market greater than $3.5 Billion.
View original content to download multimedia:http://www.prnewswire.com/news-releases/variant-pharmaceuticals-announces-publication-of-data-demonstrating-2-hydroxypropyl--cyclodextrin-2hpcd-protects-against-kidney-disease-in-experimental-models-of-alport-syndrome-as-and-focal-segmental-glomerulosclerosis-fsg-300737095.html
SOURCE Variant Pharmaceuticals, Inc.